Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation

1995 ◽  
Vol 27 (6) ◽  
pp. 769-774 ◽  
Author(s):  
I. Sasagawa ◽  
T. Nakada ◽  
Y. Kubota ◽  
T. Sawamura ◽  
K. Izumiya
Keyword(s):  
Acid Phosphatase ◽  
Luteinizing Hormone ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Hormone Analogue ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone

scholarly journals Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer

2010 ◽  
Vol 63 (7-8) ◽  
pp. 479-482 ◽  
Author(s):  
Sasa Vojinov ◽  
Goran Marusic ◽  
Ivan Levakov ◽  
Jelena Popadic-Gacesa
Keyword(s):  
Luteinizing Hormone ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Treatment Protocol ◽  
Control Group ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Therapy Effect ◽  
Androgen Blockade

% Karcinomi prostate % Antagonisti androgena % Kastracija % Testosteron % Luteinizirajuci hormone AB Introduction. The aim of this study was to investigate the influence of androgen blockades on prostate specific antigen (PSA) values in patients with locally advanced and metastatic prostatic cancer. Material and methods. The research was conducted on 60 patients. The group of 45 patients with prostatic cancer was divided into 3 subgroups, based on the type of the applied treatment protocol (15 patients on monotherapy with luteinizing hormone-releasing hormone agonists, 15 patients on total androgen blockade and 15 patients on monotherapy with antiandrogen). The control group consisted of 15 patients with benign prostatic hyperplasia. For all patients, the values of testosteron, luteinizing hormone and prostate specific antigen were monitored before as well as after 3 and 6 months during the treatment protocol. Results. All types of the applied treatment protocols in the therapy of prostatic cancer decreased the values of prostate specific antigen significantly The application of total androgen blockade and monotherapy with luteinizing hormone-releasing hormone agonists decreased the levels of prostate specific antigen significantly in comparison with monotherapy with antiandrogen. Conclusion. Although prostate specific antigen is not a prostatic cancer specific parameter, the dynamics of its decrease during the therapy of androgen blockade represents a significant marker of the therapy effect. Cilj rada je bio da se ispita uticaj androgenih blokada na vrednosti prostata specificnog antigena kod bolesnika sa lokalno uznapredovalim i metastatskim karcinomom prostate. Ispitivani uzorak se sastojao od 60 bolesnika. Grupa od 45 bolesnika sa karcinomom prostate bila je podeljena na tri podgrupe, u zavisnosti od primenjenog terapijskog protokola (15 bolesnika na monoterapiji agonistima luteinizirajuceg rilizing hormona, 15 bolesnika na totalnoj androgenoj blokadi i 15 bolesnika na monoterapiji antindrogenom). Kontrolnu grupu cinilo je 15 pacijenata sa benignom hiperplazijom prostate. Svim pacijentima su pracene vrednosti testosterona, luteinizirajuceg hormona i prostata specificnog antigena neposredno pre, kao i tri, to jest sest meseci nakon uvodjenja odgovarajuceg protokola. Sve tri vrste primenjenih terapijskih protokola u lecenju karcinoma prostate statisticki su znatno snizavale vrednosti prostata specificnog antigena u odnosu na pocetne vrednosti. Primena totalne androgene blokade i monoterapije agonistima luteinizirajuceg rilizing hormona dovela je do statisticki znatnog snizenja vrednosti prostata specificnog antigena u poredjenju sa monoterapijom antiandrogenom. Iako prostata specificni antigen nije specifican marker za karcinom prostate, dinamika njegove promene u toku androgene blokade predstavlja bitan pokazatelj terapijskog efekta.

Clinical Usefulness of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Patients with Prostatic Cancer

Tumor Biology ◽  
1990 ◽  
Vol 11 (6) ◽  
pp. 289-294 ◽  
Author(s):  
X. Filella ◽  
R. Molina ◽  
J. Jo ◽  
B. Umbert ◽  
J.L. Bedini ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Clinical Usefulness

Treatment of Prostatic Cancer with a Depot Form of a Luteinizing Hormone-Releasing Hormone Analogue

1986 ◽  
Vol 12 (6) ◽  
pp. 390-394 ◽  
Author(s):  
L. Giuliani ◽  
T. Barreca ◽  
C. Giberti ◽  
R. Franceschini ◽  
G. Martorana ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Prostatic Cancer ◽  
Hormone Analogue ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Depot Form

Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.

1986 ◽  
Vol 32 (11) ◽  
pp. 2040-2043 ◽  
Author(s):  
J K Siddall ◽  
S D Shetty ◽  
E H Cooper
Keyword(s):  
Acid Phosphatase ◽  
Disease Progression ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Carcinoma Of The Prostate ◽  
Normal Limits ◽  
Bony Metastases

Abstract We have compared the concentrations in serum of gamma-seminoprotein (gamma-SM) and prostate specific antigen (PSA), two antigens of prostatic origin that are synthesized independently of prostatic acid phosphatase (PAP, EC 3.1.3.2), to assess their potential in monitoring prostatic cancer. At presentation, 27/30 (90%) patients with metastases had a PSA concentration greater than 10 ng/mL, and 29/30 (97%) a gamma-SM concentration greater than 10 ng/mL; 21/61 (34%) with disease but without metastases had an abnormal content of PSA, and 23/61 (38%) an abnormal gamma-SM. Concentrations of PSA and gamma-SM were significantly correlated (r = 0.68, p less than 0.001). In 20 patients without metastases followed longitudinally, the median concentrations of gamma-SM, PSA, and PAP in the 13 patients who developed bony metastases or showed signs of local spreading of the tumor were 58 ng/mL, 34 ng/mL, and 2.1 U/L, respectively. The corresponding median values in the seven patients who remained clinically stable were 2.5 and 3.9 ng/mL, and 2.3 U/L. We conclude that either PSA or gamma-SM can warn of disease progression when PAP activities are still within normal limits.

Sign in / Sign up

Export Citation Format

Share Document